-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Johnson & Johnson Says Rybrevant Plus Chemotherapy Cuts Risk Of Death By 43% Versus Chemotherapy Alone When Adjusted For Crossover In Final PAPILLON Overall Survival Analysis

Benzinga·09/14/2026 05:34:57
Listen to the news
  • RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET
  • Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8%